Every investor in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are private equity firms ...
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler ...
Investors might want to bet on Lexicon Pharmaceuticals (LXRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
Mike Exton, Chief Executive Officer, highlighted a pivotal exclusive license agreement with Novo Nordisk for LX9851, stating "this agreement grants Novo an exclusive worldwide license to develop, ...
Lexicon Pharmaceuticals currently offers three late-stage assets - Zynquista, Inpefa, and pilavapadin - each with high-reward potential but significant regulatory and commercial risks. Zynquista's ...
An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback